Hirotaka Watada Selected Research

Dipeptidyl-Peptidase IV Inhibitors

1/2023	Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study.
1/2022	Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
1/2021	Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study.
1/2021	Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
1/2019	Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
6/2018	Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial.
10/2017	Dose-Dependent Effect of Sitagliptin on Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Post Hoc Analysis.
3/2017	Changes in carotid intima-media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation.
1/2017	The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation.
1/2017	Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139-148.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hirotaka Watada Research Topics

Disease

151	Type 2 Diabetes Mellitus (MODY) 05/2024 - 07/2002
55	Insulin Resistance 01/2024 - 05/2003
32	Atherosclerosis 12/2023 - 04/2004
26	Body Weight (Weight, Body) 11/2023 - 12/2005
25	Hypoglycemia (Reactive Hypoglycemia) 02/2024 - 08/2004
21	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 06/2006
20	Hyperglycemia 01/2021 - 06/2005
12	Hypertension (High Blood Pressure) 01/2024 - 04/2007
12	Diabetes Mellitus 11/2023 - 06/2005
10	Carotid Artery Diseases 01/2023 - 10/2006
9	Glucose Intolerance 01/2024 - 01/2002
8	Diabetic Nephropathies (Diabetic Nephropathy) 01/2023 - 01/2003
8	Albuminuria 01/2023 - 03/2003
7	Chronic Renal Insufficiency 04/2024 - 01/2020
7	Weight Gain 01/2023 - 12/2009
7	Inflammation (Inflammations) 12/2022 - 10/2006
6	Neoplasms (Cancer) 01/2024 - 03/2017
6	Weight Loss (Weight Reduction) 01/2022 - 08/2007
5	Heart Failure 01/2023 - 01/2014
5	Dementia (Dementias) 04/2021 - 11/2013
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 04/2010
4	Sarcopenia 01/2024 - 12/2022
4	Dyslipidemias (Dyslipidemia) 09/2023 - 01/2014
4	Graves Disease (Basedow Disease) 01/2023 - 10/2014
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2021 - 08/2007
4	Obesity 09/2021 - 06/2006
4	Thyrotoxicosis 12/2017 - 01/2014
4	Stroke (Strokes) 01/2015 - 04/2009
3	Starvation 04/2024 - 01/2019
3	Fibrosis (Cirrhosis) 09/2023 - 06/2006
3	Prediabetic State (Prediabetes) 12/2022 - 01/2015
3	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 10/2019
2	Kidney Diseases (Kidney Disease) 04/2024 - 04/2020
2	Osteophyte 12/2023 - 09/2023
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 11/2023 - 01/2020
2	Endotoxemia 06/2023 - 01/2019

Drug/Important Bio-Agent (IBA)

97	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 01/2002
80	Insulin (Novolin)FDA Link 11/2023 - 05/2003
26	LipidsIBA 02/2024 - 06/2005
21	Hypoglycemic Agents (Hypoglycemics)IBA 11/2023 - 08/2004
17	Sitagliptin Phosphate (Januvia)FDA Link 06/2019 - 03/2014
15	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2023 - 01/2013
15	Blood Glucose (Blood Sugar)IBA 05/2021 - 02/2006
13	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2023 - 03/2014
10	6- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA 01/2023 - 03/2014
10	Glucagon-Like Peptide 1 (GLP 1)IBA 04/2022 - 09/2008
10	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 09/2021 - 07/2013
9	Triglycerides (Triacylglycerol)IBA 01/2024 - 06/2006
9	LinagliptinIBA 09/2020 - 07/2011
8	Nonesterified Fatty Acids (NEFA)IBA 01/2024 - 06/2005
8	SodiumIBA 12/2022 - 03/2014
8	Metformin (Glucophage)FDA LinkGeneric 01/2021 - 04/2007
7	Glucagon (Glukagon)FDA Link 11/2023 - 12/2012
7	alogliptinIBA 01/2023 - 01/2013
6	Biomarkers (Surrogate Marker)IBA 01/2023 - 03/2014
6	Sodium-Glucose Transport ProteinsIBA 01/2023 - 04/2014
6	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 04/2007
6	Insulin Glargine (Lantus)FDA Link 01/2020 - 02/2006
6	Nateglinide (Starlix)FDA LinkGeneric 09/2015 - 08/2004
5	Pioglitazone (Actos)FDA Link 01/2015 - 01/2009
4	Proteins (Proteins, Gene)FDA Link 04/2024 - 03/2015
4	Protons (Proton)IBA 12/2023 - 01/2013
4	Fatty Acids (Saturated Fatty Acids)IBA 01/2023 - 05/2008
4	Hormones (Hormone)IBA 01/2023 - 09/2014
4	CreatinineIBA 01/2023 - 03/2003
4	AlbuminsIBA 01/2023 - 04/2009
4	insulin degludecIBA 01/2023 - 01/2015
4	IodineIBA 01/2023 - 11/2014
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 04/2005
4	voglibose (Basen)IBA 06/2018 - 04/2006
4	Glycoside Hydrolase InhibitorsIBA 05/2016 - 07/2007
3	empagliflozinIBA 04/2024 - 04/2016
3	imegliminIBA 11/2023 - 01/2022
3	Glucagon-Like Peptide-1 Receptor AgonistsIBA 04/2022 - 02/2011
3	CanagliflozinIBA 01/2022 - 04/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2016
3	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 02/2011
3	semaglutideIBA 12/2021 - 01/2018
3	IDegLiraIBA 09/2021 - 12/2019
3	Thyroxine (Levothyroxine)FDA LinkGeneric 02/2021 - 10/2014
3	EnzymesIBA 01/2021 - 03/2017
3	PotassiumIBA 01/2021 - 04/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 06/2009
3	AdiponectinIBA 01/2021 - 01/2017
3	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2019 - 01/2018
3	firuglipelIBA 01/2019 - 01/2018
3	VildagliptinIBA 12/2017 - 07/2014
3	Insulin Lispro (Humalog)FDA Link 07/2017 - 01/2017
3	Acarbose FDA LinkGeneric 05/2016 - 06/2006
3	Long-Acting Thyroid Stimulator (LATS)IBA 01/2016 - 10/2014
3	Transcription Factors (Transcription Factor)IBA 11/2015 - 01/2002
3	ApolipoproteinsIBA 01/2015 - 07/2007
3	Atorvastatin (Lipitor)FDA Link 05/2013 - 06/2005
3	candesartanIBA 04/2007 - 06/2006
3	Angiotensin II Type 1 Receptor BlockersIBA 04/2007 - 06/2006
2	lipopolysaccharide-binding proteinIBA 06/2023 - 01/2019
2	CalciumIBA 01/2023 - 12/2022

Therapy/Procedure

52	Therapeutics 01/2024 - 12/2004
39	Glycemic Control 05/2024 - 08/2004
3	Exercise Therapy (Therapy, Exercise) 06/2018 - 06/2005